A Game-Changer for Alzheimer's Detection: At-Home Blood Tests Now Accurate Enough for Research

The National Institutes of Health (NIH) has released its 2025 research progress report showing significant advances in Alzheimer's disease and related dementias research, with major developments in diagnostic capabilities and treatment approaches. The report highlights how decades of NIH-funded research into amyloid proteins and brain imaging technologies are now enabling more precise diagnosis and treatment strategies.

What Are the Latest Breakthroughs in Alzheimer's Research?

The most notable recent milestone has been the FDA approval of anti-amyloid immunotherapies that can slow progression of early Alzheimer's disease. These treatments build directly on decades of NIH investments in basic research, particularly studies of amyloid proteins and the development of amyloid PET imaging technology that was central to the clinical trials.

The timing is critical given the scope of the challenge. An estimated 7.1 million Americans currently live with Alzheimer's symptoms, and projections show this number will reach 13.9 million by 2060. Worldwide, more than 50 million people have some form of dementia.

How Many Clinical Trials Are Currently Testing New Treatments?

As of the end of fiscal year 2024, NIH was funding an impressive 495 clinical trials for Alzheimer's and related dementias. This massive research effort includes more than 225 clinical trials specifically testing both drug and non-drug interventions to treat or prevent these diseases.

The research approach has evolved to embrace precision medicine, recognizing that dementia affects different people in different ways. Many individuals diagnosed with Alzheimer's or related dementia actually have multiple disease pathologies contributing to their symptoms, a condition called mixed dementia that is now recognized as the most common form.

Current NIH-funded research spans multiple therapeutic approaches:

• Drug Development: Testing 68 clinical trials of promising drug candidates, including both entirely new medications and repurposed existing drugs
• Diagnostic Innovation: Advancing amyloid PET imaging and other biomarker technologies that can detect brain changes before symptoms appear
• Precision Medicine: Developing targeted interventions based on individual disease pathways and risk factors
• Mixed Pathology Research: Understanding how multiple disease processes interact in the brain to cause cognitive decline

Why Is the Precision Medicine Approach So Important?

Earlier research has shown that a single dementia diagnosis may reflect a complex interplay of cellular and functional changes that vary significantly between individuals. This understanding has led NIH to invest heavily in diversifying its clinical and translational dementia research portfolio.

The research strategy focuses on finding "the right intervention at the right stage for each person," moving away from one-size-fits-all approaches. This is particularly important because the ongoing studies are evaluating an increasingly diverse set of potential drug targets and behavioral and lifestyle changes.

The 2025 progress report also notes that NIH continues to ensure its research strategy is guided by the latest science. In December 2024, the National Academies of Science, Engineering, and Medicine released a congressionally mandated study titled "Preventing and Treating Dementia: Research Priorities to Accelerate Progress," which identified existing research areas to strengthen and new opportunities to explore.

These advances represent significant progress toward the ultimate goals of treating and preventing dementia across different populations. The combination of approved treatments, expanded clinical trials, and precision medicine approaches offers hope for the millions of Americans and their families affected by these devastating diseases.